Literature DB >> 23313257

Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study.

C Honoré1, D Goéré, M Messager, A Souadka, F Dumont, G Piessen, D Elias, C Mariette.   

Abstract

INTRODUCTION: The poor prognosis of signet ring cell (SRC) eso-gastric adenocarcinoma (EGA) might be explained by its great affinity for the peritoneum. The aim of this study was to identify predictors of peritoneal carcinomatosis recurrence (PCR) after curative surgery and hence identify high risk patients.
METHODS: A retrospective national survey was conducted over 19 French surgical centers between 1997 and 2010. Patients with non-metastatic disease who benefited from curative surgery without postoperative death were included. Event-free patients who did not reach the time point of 24 months were excluded.
RESULTS: In a cohort of 3010 patients, 1050 were SRC EGA and 424 patients met the selection criteria. The tumor location was mainly gastric (68.9%) and a total gastrectomy was performed in 218 patients (51.4%). Chemoradiotherapy or chemotherapy alone was given preoperatively to 71 (16.7%) and postoperatively to 150 (35.4%) patients. After a median follow-up of 54 months, recurrence was diagnosed in 214 patients (50.5%) within a mean delay of 17 ± 10.7 months. PCR was diagnosed in 81 patients (19.1%). In multivariable analysis, four factors were identified as predictors of PCR: linitis plastica (p < 0.001; OR = 4.83), tumor invasion of/or through the peritoneal serosa (p = 0.022; OR = 1.58), lymph node involvement (p = 0.005; OR = 1.7) and tumors of gastric origin (p = 0.026; OR = 2.36), with PCR rates of 55%, 26%, 23% and 22%, respectively.
CONCLUSION: Identification of strong predictors for PCR among this large series of SRC EGA patients helps to identify subgroups of patients that may benefit from specific therapeutic strategies such as prophylactic hyperthermic intraperitoneal chemotherapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23313257     DOI: 10.1016/j.ejso.2012.12.013

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

1.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

2.  Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.

Authors:  Dilsa Mizrak Kaya; Graciela M Nogueras-González; Kazuto Harada; Fatemeh G Amlashi; Sinchita Roy-Chowdhuri; Jeannelyn S Estrella; Prajnan Das; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Aurelio Matamoros; Irene Thomas; Quan Lin; Brian D Badgwell; Jaffer A Ajani
Journal:  J Surg Oncol       Date:  2017-12-04       Impact factor: 3.454

Review 3.  Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip).

Authors:  Beate Rau; Linda Feldbrügge; Felix Gronau; Miguel Enrique Alberto Vilchez; Peter Thuss-Patience; Pierre Emmanuel Bonnot; Olivier Glehen
Journal:  Visc Med       Date:  2022-02-23

4.  Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses.

Authors:  Amine Souadka; Hajar Essangri; Mohammed Anass Majbar; Amine Benkabbou; Saber Boutayeb; Benoit You; Olivier Glehen; Raouf Mohsine; Naoual Bakrin
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 5.  Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery.

Authors:  Biying Huang; Ioannis Rouvelas; Magnus Nilsson
Journal:  Ann Gastroenterol Surg       Date:  2022-03-24

Review 6.  Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.

Authors:  Simon Pernot; Thibault Voron; Geraldine Perkins; Christine Lagorce-Pages; Anne Berger; Julien Taieb
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

7.  Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study.

Authors:  Shuairan Zhang; Yang Liu; Zihan Jiao; Zenan Li; Jin Wang; Ce Li; Xiujuan Qu; Ling Xu
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

8.  Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study.

Authors:  Tao Shi; Xueru Song; Qin Liu; Yang Yang; Lixia Yu; Baorui Liu; Jia Wei
Journal:  Cancer Med       Date:  2019-08-25       Impact factor: 4.452

9.  Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology.

Authors:  Moniek Hp Verstegen; Mitchell Harker; Carlijn van de Water; Jolanda van Dieren; Niek Hugen; Iris D Nagtegaal; Camiel Rosman; Rachel S van der Post
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

10.  Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: retrospective case series.

Authors:  Amine Souadka; Mohammed Anass Majbar; Amine Benkabbou; Badr Serji; Tarik Souiki; Sidi Mohammed Bouchentouf; Mourad Abid; Basma El Khannousi; Tijani El Harroudi; Hadj Omar El Malki; Mohammed Raiss; Lahsen Ifrine; Khalid Mazaz; Aziz Zentar; Raouf Mohsine; Abdelilah Souadka; Abdelkader Belkouchi; Mohammed Ahallat; Abdelmalek Hrora
Journal:  BMC Cancer       Date:  2019-10-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.